DP1 prostanoid receptor activation will increase the severity of an acute decrease respiratory viral an infection in mice through TNF-α-induced immunopathology
Respiratory syncytial virus (RSV) bronchiolitis is a number one explanation for toddler hospitalization and mortality. We beforehand recognized that prostaglandin D2 (PGD2), launched following RSV an infection of main human airway epithelial cells or pneumonia virus of mice (PVM) an infection of neonatal mice, elicits pro- or antiviral innate immune responses as a consequence of D-type prostanoid receptor 2 (DP2) or DP1 activation, respectively. Right here, we sought to find out whether or not remedy with the DP1 agonist BW245c decreases the severity of bronchiolitis in PVM-infected neonatal mice.
In step with earlier findings, BW245c remedy elevated IFN-λ manufacturing and decreased viral load in week 1 of the an infection. Nevertheless, unexpectedly, BW245c remedy elevated mortality in week 2 of the an infection. This elevated morbidity was related to viral unfold to the parenchyma, an elevated mobile infiltrate of TNF-α-producing cells (neutrophils, monocytes, and CD4+ T cells), and the heightened manufacturing of the pro-inflammatory cytokines TNF-α, IL-6, and IL-1β. These phenotypes, in addition to the elevated mortality, have been considerably attenuated following the administration of anti-TNF-α to PVM-infected, BW245c-treated mice.
In abstract, pharmacological activation of the DP1 receptor in PVM-infected neonatal mice boosts antiviral innate and adaptive immunity, nevertheless, that is finally detrimental, as a consequence of elevated TNF-α-induced morbidity and mortality. We then give attention to the deployment of convalescent plasma and neutralizing mAbs for remedy of SARS-CoV-2. We assessment particular scientific questions, together with the rationale for stratification of sufferers, potential biomarkers, identified threat components and temporal issues for optimum scientific use.
To reply these questions, there’s a want to grasp components such because the kinetics of viral load and its correlation with scientific outcomes, endogenous antibody responses, pharmacokinetic properties of neutralizing mAbs and the potential profit of mixing antibodies to defend in opposition to rising viral variants. Antibody remedy depleting NK cells previous to RSV an infection resulted in stopping extreme weight reduction and histopathology, in addition to attenuating infiltration of dendritic cell subsets and TNF-α+ T cells within the lungs.

Pure killer cells contribute to enhanced respiratory illness after oil-in-water emulsion adjuvanted vaccination in opposition to respiratory syncytial virus and an infection
Respiratory syncytial virus (RSV) an infection precipitated extreme acute respiratory illness in kids and the aged. There is no such thing as a licensed vaccine. It has been a difficult drawback to keep away from vaccine enhanced respiratory illness in creating a protected and efficient RSV vaccine. Right here, we investigated the influence of MF59-like oil-in-water emulsion adjuvant Addavax on the vaccine efficacy of inactivated cut up RSV (sRSV) and the roles of pure killer (NK) cells in enhanced respiratory illness in sRSV vaccinated mice after RSV an infection.
Addavax-adjuvanted sRSV vaccination induced larger ranges of IgG1 isotype antibodies and simpler lung viral clearance upon RSV an infection however promoted enhanced respiratory illness of weight reduction, pulmonary irritation, and NK and NK T (NKT) cell infiltrations within the lungs. This examine demonstrated the impacts of oil-in-water emulsion adjuvant on sRSV vaccination and the potential roles of NK and NKT cells in safety and respiratory illness after adjuvanted RSV vaccination and an infection in a mouse mannequin.
pPACK-SPIKE Alpha Combo Kit, includes Cat# CVD19-590A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-599A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE Gamma Combo Kit, includes Cat# CVD19-630A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-639A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE Beta Combo Kit, includes Cat# CVD19-640A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-649A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE Delta Combo Kit, includes Cat# CVD19-650A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-659A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE Omicron Combo Kit, includes Cat# CVD19-660A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-669A-KIT |
SBI |
1 kit |
EUR 1162 |
pPACK-SPIKE B.1.429 Combo Kit, includes Cat# CVD19-610A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-619A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE B.1.525 Combo Kit, includes Cat# CVD19-620A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-629A-KIT |
SBI |
1 kit |
EUR 1141 |
Human Glucose concentration-Glucose concentration- ELISA Kit |
QY-E05365 |
Qayee Biotechnology |
96T |
EUR 400 |
pPACK-SPIKE B.1.351 RBD Mutations Combo Kit, includes Cat# CVD19-580A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-589A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE B.1.351 S1 Mutations Combo Kit, includes Cat# CVD19-600A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-609A-KIT |
SBI |
1 kit |
EUR 1141 |
Gas concentration agent |
nBIONIX-A07 |
Bulldog Bio |
20 |
EUR 138 |
ETHANOL, 70% CONCENTRATION |
IB15727 |
IBI Scientific |
10L |
EUR 210.13 |
Description: BOX W/SPIGOT (HAZ) |
Denhardt's solution, 100x Concentrate |
D0062 |
Bio Basic |
25ml |
EUR 82.97 |
|
Wash Solution Concentrate (HPE) |
DS0024-125ML |
EWC Diagnostics |
1 unit |
EUR 141.01 |
Description: Wash Solution Concentrate (HPE) |
Wash Solution Concentrate (HPE) |
DS0024-250ML |
EWC Diagnostics |
1 unit |
EUR 280.84 |
Description: Wash Solution Concentrate (HPE) |
Lentivirus concentration reagent |
E28F06205 |
EnoGene |
100ml |
EUR 336.51 |
Prewash Solution Concentrate (PW) |
DS0011-400ML |
EWC Diagnostics |
1 unit |
EUR 240.82 |
Description: Prewash Solution Concentrate (PW) |
X-Gal Solution, 40 mg/ml concentrate |
X0321-005 |
GenDepot |
5X1ml |
EUR 45 |
X-Gal Solution, 40 mg/ml concentrate |
X0321-020 |
GenDepot |
20ml |
EUR 70 |
Minimal Inhibitory Concentration Kit |
K195-2500 |
Biovision |
each |
EUR 836.4 |
Minimal Inhibitory Concentration Kit |
K195-500 |
Biovision |
each |
EUR 574.8 |
AvaI -HC unit: 330, High Concentration |
YRAVA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
SacI -HC unit: 1500, High Concentration |
YRSAC1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Concentrating Solution for Sirius Red Total Collagen Detection Other |
90626 |
Chondrex |
50 ml |
EUR 14 |
Description: Concentrating Solution for Sirius Red Total Collagen Detection Kit |
Kpn I -HC unit: 5000, High Concentration |
YRKPN1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Msp I -HC unit: 1400, High Concentration |
YRMSP1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Nco I -HC unit: 400, High Concentration |
YRNCO1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Pst I -HC unit: 12000, High Concentration |
YRPST1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Pvu II -HC unit: 2000, High Concentration |
YRPVU2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Rsa I -HC unit: 800, High Concentration |
YRRSA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Sal I -HC unit: 2200, High Concentration |
YRSAL1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Sma I -HC unit: 1500, High Concentration |
YRSMA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Taq I -HC unit: 410, High Concentration |
YRTAQ1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Xba I -HC unit: 3000, High Concentration |
YRXBA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Xho I -HC unit: 5000, High Concentration |
YRXHO1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Hi-SYBr Master Mix (Concentration 2X) |
MBT074-0.5ML |
EWC Diagnostics |
1 unit |
EUR 54.43 |
Description: Hi-SYBr Master Mix (Concentration 2X) |
Hi-SYBr Master Mix (Concentration 2X) |
MBT074-1ML |
EWC Diagnostics |
1 unit |
EUR 104.64 |
Description: Hi-SYBr Master Mix (Concentration 2X) |
Hi-SYBr Master Mix (Concentration 2X) |
MBT074-5ML |
EWC Diagnostics |
1 unit |
EUR 418.52 |
Description: Hi-SYBr Master Mix (Concentration 2X) |
Dra I-HC unit: 3500, High Concentration |
YRDRA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
EcoR I -HC unit: 12000, High Concentration |
YRECOR1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
BamH I-HC unit: 12000, High Concentration |
YRBAMH1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Bgl II-HC unit: 2500, High Concentration |
YRBGL2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
EcoR V-HC unit: 2000, High Concentration |
YRECOR5-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Hind III -HC unit: 12000, High Concentration |
YRHIND3-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Hinf I-HC unit: 2000, High Concentration |
YRHINF1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
ViaCheck™ Concentration Control (0.5 × 106) |
VC50N-20 |
Polysciences Europe GmbH |
20 mL |
EUR 247.32 |
Description: HS Code : 38220000 |
ViaCheck Concentration Control 1 x 106 |
VC60N-20 |
Bangs Laboratories |
20 ml |
EUR 251.33 |
Description: ViaCheck Concentration Control 1 x 106 mimic the characteristics of live and dead cells in the trypan blue dye exclusion method and may be used to support validation and QC of image-based cell viability analyzers |
ViaCheck Concentration Control 4 x 106 |
VC70N-20 |
Bangs Laboratories |
20 ml |
EUR 367.48 |
Description: ViaCheck Concentration Control 4 x 106 mimic the characteristics of live and dead cells in the trypan blue dye exclusion method and may be used to support validation and QC of image-based cell viability analyzers |
ViaCheck Concentration Control 8 x 106 |
VC80N-20 |
Bangs Laboratories |
20 ml |
EUR 410.53 |
Description: ViaCheck Concentration Control 8 x 106 mimic the characteristics of live and dead cells in the trypan blue dye exclusion method and may be used to support validation and QC of image-based cell viability analyzers |
Cas9 Nuclease Protein (High Concentration) |
K108 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 80 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
UPCK™ Urine Protein Concentration Kit |
UPCK-25 |
Biotech Support Group |
25 preps |
EUR 1143.6 |
Description: Urine Protein Enrichment Kit |
BssH II-HC unit: 200, High Concentration |
YRBSSH2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
BstE II-HC unit: 1300, High Concentration |
YRBSTE2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
EcoT38 I -HC unit: 900, High Concentration |
YRECOT38-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Hae III-HC unit: 3400, High Concentration |
YRHAE3-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Hinc II-HC unit: 500, High Concentration |
YRHINC2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
saCas9 Nuclease Protein (High Concentration) |
K144 |
ABM |
32.5 µg (250pmol) Volume: 25µL |
EUR 155 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). |
BCA Protein concentration determination kit |
BC016-500ml |
ELK Biotech |
500ml |
EUR 110 |
Cas9 Null Mutant Protein (High Concentration) |
K140 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type Cas9 (D10A and H840A). Such a Cas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, unlike Cas9 Nuclease and Cas9 Nickase, where permanent gene disruption can be achieved, the Cas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
Cas9 Nuclease NLS Protein (High Concentration) |
K130 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 80 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. Cas9 Nuclease NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
Cas9 Nickase D10A Protein (High Concentration) |
K132 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;;To counteract off-target mutagenic effects of this system, the Cas9 Nickase D10A was developed with a D10A mutation in its RuvC1 nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single-stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
dNTP SET, Concentration: 100mM, 4x1ml
set of dNTP consisting 4 separate tubes (4x1ml) each with 100mM concentration of dATP, dGTP, dCTP, and dTTP. |
2013SET |
ACTGene |
each |
EUR 361.42 |
|
Myoglobin Concentration ELISA Quantitation Kit |
GWB-E1E945 |
GenWay Biotech |
ELISA_Kits |
Ask for price |
Cas9 Nickase H840A Protein (High Concentration) |
K136 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;;To improve the off-target mutagenic effects of this system, the Cas9 Nickase H840A Protein was developed with a H840A mutation in its HNH-like nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single-stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
saCas9 Null Mutant Protein (High Concentration) |
K146 |
ABM |
32.5 µg (250pmol) Volume: 25µL |
EUR 155 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The saCas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type saCas9. Such a saCas9 protein retains its ability to bind to genomic DNA through sgRNA:genomic DNA base pairing, however, the saCas9 Null Mutant does not induce cleavage. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). |
Taq DNA Polymerase (recombinant), Low Concentration - 500 U |
THEP0404 |
Westburg |
each |
EUR 189.66 |
AAVancedTM Concentration Reagent (100 ml aliquot) |
AAV100A-1 |
SBI |
100 ml |
EUR 462 |
AAVancedTM Concentration Reagent (250 ml aliquot) |
AAV110A-1 |
SBI |
250 ml |
EUR 928 |
fnCpf1 Nuclease NLS Protein (High Concentration) |
K187 |
ABM |
380 μg (2.5 nmol) Volume: 250µL |
EUR 365 |
Description: Using Cpf1 (a.k.a. Cas12a) in your CRISPR experiment offers several advantages over other CRISPR-associated nucleases.; - Due to the T-rich PAM sequence (TTTN), Cpf1 enables editing in regions unable to be targeted by Cas9.
- Cpf1 can be used with a shorter guide RNA (called crRNA) than Cas9.
- Cpf1 creates a staggered cut in dsDNA instead of a blunt cut.
- Cpf1 cuts distal to the PAM sequence, which may allow for multiple rounds of cleavage.
fnCpf1 is from the bacteria Francisella novicida. This protein contains a SV40 T antigen nuclear localization signal (NLS) on the N-terminus of the protein. If the cut caused by fnCpf1 is repaired by non-homologous end joining (NHEJ), an indel may be formed that disrupts the open reading frame of the targeted gene, leading to gene knockout. Alternatively, by supplying a repair template, a sequence can be knocked in at the cleavage site via homology directed repair (HDR).
|
asCpf1 Nuclease NLS Protein (High Concentration) |
K188 |
ABM |
380 μg (2.5 nmol) Volume: 250µL |
EUR 365 |
Description: Using Cpf1 (a.k.a. Cas12a) in your CRISPR experiment offers several advantages over other CRISPR-associated nucleases. ; - Due to the T-rich PAM sequence (TTTN), Cpf1 enables editing in regions unable to be targeted by Cas9.
- Cpf1 can be used with a shorter guide RNA (called crRNA) than Cas9.
- Cpf1 creates a staggered cut in dsDNA instead of a blunt cut.
- Cpf1 cuts distal to the PAM sequence, which may allow for multiple rounds of cleavage.
asCpf1 is from the bacteria Acidaminococcus. This protein contains a SV40 T antigen nuclear localization signal (NLS) on the N-terminus of the protein. If the cut caused by asCpf1 is repaired by non-homologous end joining (NHEJ), an indel may be formed that disrupts the open reading frame of the targeted gene, leading to gene knockout. Alternatively, by supplying a repair template, a sequence can be knocked in at the cleavage site via homology directed repair (HDR).
|
saCas9 Nuclease NLS Protein (High Concentration) |
K189 |
ABM |
32.5 µg (250pmol) Volume: 50µL |
EUR 155 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). saCas9 Nuclease NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
asCpf1 Nuclease NLS Protein (High Concentration) |
K088 |
ABM |
38 μg (250 pmol) Volume: 25µL |
EUR 75 |
Description: Using Cpf1 (a.k.a. Cas12a) in your CRISPR experiment offers several advantages over other CRISPR-associated nucleases.; - Due to the T-rich PAM sequence (TTTN), Cpf1 enables editing in regions unable to be targeted by Cas9.
- Cpf1 can be used with a shorter guide RNA (called crRNA) than Cas9.
- Cpf1 creates a staggered cut in dsDNA instead of a blunt cut.
- Cpf1 cuts distal to the PAM sequence, which may allow for multiple rounds of cleavage.
asCpf1 is from the bacteria Acidaminococcus. This protein contains a SV40 T antigen nuclear localization signal (NLS) on the N-terminus of the protein. If the cut caused by asCpf1 is repaired by non-homologous end joining (NHEJ), an indel may be formed that disrupts the open reading frame of the targeted gene, leading to gene knockout. Alternatively, by supplying a repair template, a sequence can be knocked in at the cleavage site via homology directed repair (HDR).
|
saCas9 Nuclease NLS Protein (High Concentration) |
K089 |
ABM |
6.5 µg (50pmol) Volume: 50µL |
EUR 55 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). saCas9 Nuclease NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
Cas9 Null Mutant NLS Protein (High Concentration) |
K142 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type Cas9 (D10A and H840A). Such a Cas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, unlike Cas9 Nuclease and Cas9 Nickase, where permanent gene disruption can be achieved, the Cas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. Cas9 Null Mutant NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
96 Well Plate RNA Cleanup and Concentration Kit |
BRC1251 |
Bio Basic |
2xPlates, 192prep |
EUR 300.37 |
|
Rat Tail Collagen I, High concentration, 10mg/ml |
NAT-0021 |
Creative BioMart |
5mL |
EUR 704 |
Cas9 Nuclease GFP NLS Protein (High Concentration) |
K148 |
ABM |
47µg (250pmol) Volume: 25µL |
EUR 155 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR). ;The Cas9 from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. ;The fusion of Cas9 Nuclease NLS to GFP allows for visual confirmation of transfection as well as subsequent verification of Cas9 clearance from the cells. Cas9 Nuclease-GFP can also be used for FACS applications and screening. Cas9 Nuclease-GFP NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. Our Cas9-GFP proteins have the Enhanced green fluorescent protein (eGFP). |
Cas9 Nickase D10A NLS Protein (High Concentration) |
K134 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;;To counteract off-target mutagenic effects of this system, the Cas9 Nickase D10A was developed with a D10A mutation in its RuvC1 nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single-stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. Cas9 D10A Nickase NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
Cas9 Nickase H840A NLS Protein (High Concentration) |
K138 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;;To improve the off-target mutagenic effects of this system, the Cas9 Nickase H840A Protein was developed with a H840A mutation in its HNH-like nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single-stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. Cas9 H840 Nickase NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. Cas9 H840 Nickase NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
saCas9 Null Mutant NLS Protein (High Concentration) |
K147 |
ABM |
32.5 µg (250pmol) Volume: 25µL |
EUR 155 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The saCas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type saCas9. Such a saCas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, the saCas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;; The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). saCas9 NLS Null Mutant contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
ProteoSpin™ Urine Protein Concentration Midi Kit |
52300 |
Norgen Biotek Corp |
10 Preps |
EUR 171 |
ProteoSpin™ Urine Protein Concentration Maxi Kit |
21600 |
Norgen Biotek Corp |
4 Preps |
EUR 89.4 |
RNA Clean-Up and Concentration Micro-Elute Kit |
61000 |
Norgen Biotek Corp |
50 Preps |
EUR 197.4 |
Cas9 Null Mutant GFP NLS Protein (High Concentration) |
K186 |
ABM |
47µg (250pmol) Volume: 25µL |
EUR 155 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;The Cas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type Cas9 (D10A and H840A). Such a Cas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, unlike Cas9 Nuclease and Cas9 Nickase, where permanent gene disruption can be achieved, the Cas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression. ;The Cas9 from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. ;The fusion of Cas9 to GFP allows for visual confirmation of transfection as well as subsequent verification of Cas9 clearance from the cells. Cas9 Null Mutant GFP can also be used for FACS applications and screening. Cas9 D10A Null Mutant GFP NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
Cas9 D10A Nickase GFP NLS Protein (High Concentration) |
K149 |
ABM |
47µg (250pmol) Volume: 25µL |
EUR 155 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;To counteract off-target mutagenic effects of this system, the Cas9 Nickase D10A was developed with a D10A mutation in its RuvC1 nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements. ;The Cas9 from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. ;The fusion of Cas9 to GFP allows for visual confirmation of transfection as well as subsequent verification of Cas9 clearance from the cells. Cas9 D10A Nickase-GFP can also be used for FACS applications and screening. Cas9 D10A Nickase -GFP NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
ViaCheck™ Concentration Control (0.5 × 106) SingleShots™ |
VC50NSS-25 |
Polysciences Europe GmbH |
25 vials |
EUR 304.56 |
Description: HS Code : 38220000 |
ViaCheck™ Concentration Control (0.5 × 106) SingleShots™ |
VC50NSS-75 |
Polysciences Europe GmbH |
75 vials |
EUR 817.56 |
Description: HS Code : 38220000 |
ViaCheck™ Concentration Control (1 × 106) SingleShots™ |
VC60NSS-25 |
Polysciences Europe GmbH |
25 vials |
EUR 304.56 |
Description: HS Code : 38220000 |
ViaCheck™ Concentration Control (1 × 106) SingleShots™ |
VC60NSS-75 |
Polysciences Europe GmbH |
75 vials |
EUR 817.56 |
Description: HS Code : 38220000 |
ViaCheck™ Concentration Control (4 × 106) SingleShots™ |
VC70NSS-25 |
Polysciences Europe GmbH |
25 vials |
EUR 444.96 |
Description: HS Code : 38220000 |
ViaCheck™ Concentration Control (4 × 106) SingleShots™ |
VC70NSS-75 |
Polysciences Europe GmbH |
75 vials |
EUR 1198.8 |
Description: HS Code : 38220000 |
ViaCheck™ Concentration Control (8 × 106) SingleShots™ |
VC80NSS-25 |
Polysciences Europe GmbH |
25 vials |
EUR 484.92 |
Description: HS Code : 38220000 |
ViaCheck™ Concentration Control (8 × 106) SingleShots™ |
VC80NSS-75 |
Polysciences Europe GmbH |
75 vials |
EUR 1308.96 |
Description: HS Code : 38220000 |
Detergent Critical Micelle Concentration (CMC) Assay Kit |
CMC1000 |
ProFoldin |
1000 assays |
EUR 204.71 |
Description: This product includes 100 ul of 1000 x CMC dye. It is for measurement of 1000 samples using 96-well plates. It can also be used for determination of detergent CMC values using cuvettes. |
Linsmaier and Skoog Vitamin Concentration (Syringe Vials) |
30630046-1 |
Bio-WORLD |
100 mL |
EUR 55.96 |
5X COOMASSIEnano Concentrate Protein Staining Solution, 1L |
PS002-L05X |
Bio-Helix |
1L |
EUR 200 |
CleanAll DNA/RNA Clean-Up and Concentration Micro Kit |
23800 |
Norgen Biotek Corp |
50 Preps |
EUR 153 |
Non-Interfering Protein Concentration Determination Kit |
SK3071 |
Bio Basic |
250Assays, 250preps |
EUR 130.99 |
|
Murashige & Skoog (Modification No. 1) ½ concentration Macroele |
TS1069-10L |
EWC Diagnostics |
1 unit |
EUR 3.72 |
Description: Murashige & Skoog (Modification No. 1) ½ concentration Macroelements |
Murashige & Skoog (Modification No. 1) ½ concentration Macroele |
TS1069-25L |
EWC Diagnostics |
1 unit |
EUR 7.74 |
Description: Murashige & Skoog (Modification No. 1) ½ concentration Macroelements |
CORNING® HIGH CONCENTRATION SYNTHEMAX® II,1 VIAL, 10G |
3784 |
CORNING |
10g/pk |
EUR 307.2 |
Description: Microcarriers; Corning Microcarriers |
A number of neutralizing monoclonal antibodies (mAbs) to extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are actually underneath analysis in scientific trials. With the US Meals and Drug Administration lately granting emergency use authorizations for neutralizing mAbs in non-hospitalized sufferers with mild-to-moderate COVID-19, there may be an pressing want to debate the broader potential of those novel therapies and to develop methods to deploy them successfully in scientific observe, given restricted preliminary availability. Right here, we assessment the precedent for passive immunization and classes discovered from utilizing antibody therapies for viral infections similar to respiratory syncytial virus, Ebola virus and SARS-CoV infections.